Uracil Derivative Radiation Potentiator for Toxicity Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current radiation therapy for cancer, especially in advanced stages, faces challenges with high doses causing adverse effects such as blood toxicity and digestive issues, and existing radiation sensitizers often have neurotoxicity limitations, hindering effective treatment duration and efficacy.
Innovation Solution
The use of uracil derivatives, represented by formula (1), as a radiation therapy potentiator, which, when combined with low-dose radiation, enhances anti-tumor effects comparable to high-dose radiation therapy while mitigating adverse effects, thereby allowing for longer treatment periods with reduced toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high-dose radiation therapy is used to treat advanced cancer, then anti-tumor effect is improved, but adverse effects such as blood toxicity and digestive issues worsen
Solution Approach 1:
The patent introduces a radiation potentiator as an intermediary substance that enhances the effectiveness of radiation therapy. This potentiator acts as a mediator between the radiation and tumor cells, allowing lower radiation doses to achieve the same anti-tumor effect, thereby reducing adverse effects while maintaining treatment efficacy.
Solution Approach 2:
The patent changes the parameter of radiation dose by using a potentiator to enhance radiation sensitivity. Instead of increasing the radiation dose to improve anti-tumor effect, the invention modifies the biological parameter of tissue sensitivity through the potentiator, enabling lower physical doses to achieve the same therapeutic effect.
2Object-affected harmful factors
If existing radiation sensitizers are used to reduce radiation dose, then adverse effects are reduced, but neurotoxicity limits their effectiveness
Solution Approach 1:
The patent employs a radiation potentiator that can be administered continuously during radiation therapy without causing long-term neurotoxicity. Unlike traditional sensitizers that require careful dose management to avoid neurotoxicity, this potentiator provides sustained sensitization activity throughout the treatment course without accumulating harmful effects.
Solution Approach 2:
The patent converts the potential harm of neurotoxicity associated with traditional radiation sensitizers into a benefit by using a potentiator that enhances radiation sensitivity without causing neurotoxicity. The invention turns the limitation of existing sensitizers into an advantage by finding an alternative mechanism that achieves sensitization without the harmful side effects.
3Reliability
If combined therapy of chemotherapeutic agent and radiotherapy is used, then anti-tumor effect is improved, but adverse effects and treatment interruption worsen
Solution Approach 1:
The patent uses a radiation potentiator as an intermediary that enhances radiation therapy without requiring combination with chemotherapeutic agents. This potentiator serves as a bridge that allows radiation alone to achieve enhanced anti-tumor effects, eliminating the need for concurrent chemotherapy and its associated adverse effects and treatment interruptions.
Solution Approach 2:
The patent extracts the essential function of combination therapy (enhancing anti-tumor effect) and separates it from the harmful component (chemotherapeutic agent). By using a radiation potentiator, the invention extracts the beneficial sensitization effect while removing the toxic chemotherapy component, achieving enhanced anti-tumor activity without the adverse effects of combined modality therapy.
Data Source
AI summary
To provide a radiation therapy potentiator, which, when employed in combination with cancer radiation therapy, can reduce radiation dose and can mitigate adverse effects.The invention provides a radiation therapy potentiator containing, as an effective ingredient, a uracil derivative represented by formula (1) (wherein R1 represents a halogen atom or a cyano group; and R2 represents a 4- to 8-membered heterocyclic group having 1 to 3 nitrogen atoms and optionally having as a substituent a lower alkyl group, an imino group, a hydroxyl group, a hydroxymethyl group, a methanesulfonyloxy group, or an amino group; an amidinothio group in which a hydrogen atom attached to a nitrogen atom may be substituted by a lower alkyl group; a guanidino group in which a hydrogen atom attached to a nitrogen atom may be substituted by a lower alkyl group or a cyano group; a lower alkylamidino group; or a 1-pyrrolidinylmethyl group) or a pharmaceutically acceptable salt thereof.